Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A post-trial access (PTA) study of SHP647

Next Previous
X
Search
Trial Profile

A post-trial access (PTA) study of SHP647

Status: Planning
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Jun 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ontamalimab (Primary)
  • Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
  • Focus Therapeutic Use

    • Most Recent Events

    • 02 Jun 2020 New trial record
    • 28 May 2020 According to an Takeda media release, the parameters for this PTA study will be determined in collaboration with the SHP647 program's steering committee and relevant regulatory authorities, and subsequently launched, subject to applicable local regulations and ethical considerations. Treatment will be made available to patients enrolled in this PTA study to meet their individual treatment needs.
    • 28 May 2020 According to an Takeda media release, on May 28, the European Commission has released Takeda from the obligation to divest the pipeline compound SHP647 and certain associated rights. Takeda will discontinue the current SHP647 clinical trial program, and it will be providing all eligible trial participants with the opportunity to have continued access to SHP647 in a post-trial access (PTA) study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top